BioRestorative Therapies (NASDAQ:BRTX) Tuesday said that the U.S. Food and Drug Administration has cleared an amendment to the protocol of the ongoing Phase 2 study investigating the use of BRTX-100, ...
Source LinkBioRestorative Therapies (NASDAQ:BRTX) Tuesday said that the U.S. Food and Drug Administration has cleared an amendment to the protocol of the ongoing Phase 2 study investigating the use of BRTX-100, ...
Source Link
Comments